Alzheimer's disease (AD) is a neurodegenerative disease associated with human aging.
Ten percent of individuals over 65 years have AD and its prevalence continues to rise with …

Deficiency in cerebral amyloid β-protein (Aβ) clearance is implicated in the pathogenesis of
the common late-onset forms of Alzheimer's disease (AD). Accumulation of misfolded Aβ in …

The neurosensory retina emerges as a prominent site of Alzheimer's disease (AD)
pathology. As a CNS extension of the brain, the neuro retina is easily accessible for …

The retina has been increasingly investigated as a site of Alzheimer's disease (AD)
manifestation for over a decade. Early reports documented degeneration of retinal ganglion …

Alzheimer's disease (AD) is a common, incurable, and progressive dementia, characterized
by loss of learning and memory and the neuropathologic accumulation of amyloid plaques …

Abstract Background: Definite Alzheimer's disease (AD) diagnosis at early stages is vital for
targeting intervention, yet currently unavailable. Noninvasive detection of the pathological …

Novel, neuroprotective uses of Copaxone (generic name: glatiramer acetate—GA) are being
examined, primarily in neurological conditions involving cognitive decline. GA is a well …

Osteopontin (OPN), a matricellular immunomodulatory cytokine highly expressed by
myelomonocytic cells, is known to regulate immune cell migration, communication, and …

Weekly glatiramer acetate immunization of transgenic mice modelling Alzheimer's disease
resulted in retained cognition (Morris water maze test), decreased amyloid-β plaque burden …

Cognitive decline in patients with Alzheimer's disease (AD) is associated with elevated brain
levels of amyloid β protein (Aβ), particularly neurotoxic Aβ1–42. Angiotensin-converting …